Items Tagged ‘General Brain Cancer’

June 7th, 2016

Temodar® After Radiation Improves Survival in Anaplastic Gliomas

By

The use of the chemotherapy agent Temodar (temozolomide) following radiation therapy significantly improves time to cancer progression and overall survival among patients with newly diagnosed anaplastic glioma without 1p/19q co-deletions. These results were recently presented at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). Anaplastic gliomas are a type of brain […]

View full entry

Tags: 2016, Anaplastic gliomas, asco, Brain Cancer, CATNON trial, General Brain Cancer, News, radiation therapy, Temodar, temozolomide


May 23rd, 2016

Genetically Modified Poliovirus Granted “Breakthrough” by FDA for Glioblastoma

By

The United States Food and Drug Administration (FDA) has granted “breakthrough status” designation for the treatment of glioblastoma containing a genetically modified poliovirus. Glioblastoma is an extremely aggressive form of brain cancer, with few patients surviving 5 years following diagnosis. Despite efforts with surgery, chemotherapy, and/or radiation therapy, the overall outcomes for patients with glioblastoma […]

View full entry

Tags: Brain Cancer, breakthrough status, fda, General Brain Cancer, genetically modified polio virus, glioblastoma, immunotherapy, News


October 22nd, 2015

Optune Approved for Newly Diagnosed Glioblastoma Multiforme

By

The United States Food and Drug Administration has expanded the approval of the Optune device for the treatment of patients with newly diagnosed glioblastoma multiforme. Glioblastoma multiforme (GBM) is an extremely aggressive form of brain cancer. Average survival of patients with GBM is less than 15 months because the cancer tends to be resistant to […]

View full entry

Tags: Brain Cancer, gbm, General Brain Cancer, glioblastoma multiforme, News, Optune device, temozolomide, TTFields


July 16th, 2015

FDA Grants Fast Track Designation to Toca 511 & Toca FC for Treatment of High Grade Glioblastoma

By

Tocagen Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its lead oncology product, Toca 511 & Toca FC, for the treatment of recurrent high grade glioblastoma, which includes both glioblastoma multiforma and anaplastic astrocytoma. A clinical study called Toca 5 will be initiated later this year […]

View full entry

Tags: anaplastic astrocytoma, Brain Cancer, General Brain Cancer, glioblastoma multiforma, immune-oncology, News, Toca 5, Toca 511, Toca FC


July 13th, 2015

Researchers Recruit Herpes Virus as Part of Brain Cancer Treatment

By

A therapy that uses the herpes virus to make tumors more vulnerable to treatment appears promising in the treatment of glioblastoma multiforme (GBM), a form of brain cancer. These findings were presented at 2015 Annual Meeting of the American Society of Clinical Oncology (May 29–June 2, Chicago, Illinois) and published in the Journal of Clinical […]

View full entry

Tags: AdV-Tk, Brain Cancer, clinical trial, gbm, Gene Therapy, General Brain Cancer, gliobastoma multiforme, herpes virus, News, treatment


July 1st, 2015

Rintega® Improves Survival in Patients with Glioblastoma Multiforme

By

The immunotherapy drug Rintega® (rindopepimut) appears to improve survival among patients with relapsed glioblastoma multiforme (GBM) brain cancer. These findings were presented at 2015 Annual Meeting of the American Society of Clinical Oncology (May 29–June 2, Chicago, Illinois) and published in the Journal of Clinical Oncology. Glioblastoma multiforme is one of the most common and […]

View full entry

Tags: avastin, bevacizumab, Brain Cancer, clinical trial, EGFRvIII, gbm, General Brain Cancer, glioblastoma multiforme brain cancer, News, rindopepimut, Rintega


February 3rd, 2015

Danish Study Suggests Contraceptive Use Increases Risk of Brain Cancer

By

The results of a recently published clinical study suggest that taking the birth control pill for at least five years may double the risk of developing a glioblastoma multiforme (GBM), a rare but often fatal from of brain cancer. Glioblastoma multiforme is one of the most common and fatal types of primary brain cancer. It […]

View full entry

Tags: birth control, Brain Cancer, cancer risk, contraceptive, gbm, General Brain Cancer, glioblastoma, glioblastoma multiforme, News


September 19th, 2014

DNAtrix Announces Treatment Of First Patient With DNX-2401 In Recurrent Glioblastoma Trial

By

DNAtrix, Inc., experts in oncolytic virus development, today announced that the first patient was treated with the company’s lead product, DNX-2401, a replication competent adenovirus plus gamma interferon in a randomized, multicenter, open-label Phase Ib study for patients with recurrent glioblastoma. “DNAtrix, in collaboration with leading neurosurgeons and neuro-oncologists in the US, is pleased to […]

View full entry

Tags: adenovirus, Brain Cancer, dnx-2401, gamma interferon, gbm, General Brain Cancer, glioblastoma, News, recurrent glioblastoma


June 24th, 2014

Chemotherapy Following Radiation Improves Outcomes in Low Grade Glioblastoma

By

According to results recently presented at the 2014 annual meeting of the American Society of Clinical Onoclogy, patients with low-grade glioblastom multiforme (GBM) benefited from chemotherapy following radiation therapy compared to radiation therapy alone. consisting of procarbazine, CCNU, and vincristine (PCV) administered following radiation therapy improved progression-free survival and overall survival in adults with low-grade […]

View full entry

Tags: Brain Cancer, gbm, General Brain Cancer, glioblastom multiforme, glioblastoma, News


January 27th, 2014

Follow-Up Study Shows ICT-107 Vaccine Fails to Extend Survival in GBM

By

Despite promising results in a phase I trial, the vaccine ICT-107 failed to significantly prolong overall survival in patients with glioblastoma multiforme in a follow-up phase II trial.[1] Glioblastoma multiforme (GBM) is an aggressive type of type of brain tumor that occurs mainly in adults. Treatment often involves surgery followed by radiation and chemotherapy. With […]

View full entry

Tags: Brain Cancer, General Brain Cancer, News


December 20th, 2013

Novel Vaccine Prolongs Survival in Glioblastoma Multiforme

By

Eight of 16 patients with glioblastoma multiforme who participated in a vaccine study survived longer than fiver years after diagnosis, according to the results of a study presented at the Fourth Quadrennial Meeting of the World Federation of Neuro-Oncology. Glioblastoma multiforme (GBM) is an aggressive type of type of brain tumor that occurs mainly in […]

View full entry

Tags: Brain Cancer, General Brain Cancer, News


October 9th, 2013

No Added Toxicity with Avastin in Glioblastoma

By

The addition of Avastin® (bevacizumab) to standard chemoradiation significantly slowed the progression of glioblastoma without added toxicity, according to the results of a study presented at the annual meeting of the American Society of Radiation Oncology. Glioblastoma is a aggressive type of type of brain tumor that occurs mainly in adults. Treatment often involves surgery […]

View full entry

Tags: Brain Cancer, General Brain Cancer, News


September 25th, 2013

Antiviral Drug May Extend Survival in Glioblastoma

By

The common antiviral drug Valcyte (valganciclovir) may extend survival in glioblastoma, according to the results of a study published in the New England Journal of Medicine. Glioblastoma is one of the most common and fatal types of primary brain cancer. It develops from the glial cells, which are the most abundant cells in the nervous […]

View full entry

Tags: Brain Cancer, General Brain Cancer, News


June 7th, 2013

Avastin Doesn’t Improve Survival in Newly Diagnosed Glioblastoma

By

In a Phase III clinical trial among patients with newly diagnosed glioblastoma, the addition of Avastin® (bevacizumab) to standard chemoradiation increased side effects and did not improve overall survival. These results were presented at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO). Glioblastoma is a aggressive type of type of brain […]

View full entry

Tags: Brain Cancer, General Brain Cancer, News


May 22nd, 2013

Agenus Announces Initiation of Enrollment in NCI-Sponsored Randomized Trial of Prophage G-200 Vaccine With Avastin in Treatment of Brain Tumors

By

Study Seeking to Enroll 222 Patients; Largest Vaccine Trial Ever Funded by NCI in Brain Tumors and the Largest Cancer Vaccine Study Ever Conducted in Combination With Avastin LEXINGTON, Mass., May 22, 2013 (GLOBE NEWSWIRE) — Agenus Inc. (Nasdaq:AGEN) today announced enrollment has started for a large, randomized Phase 2 study of Prophage G-200 (Heat […]

View full entry

Tags: Brain Cancer, General Brain Cancer, News